We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Teladoc's Integrated Care Business Deserves More Attention
Read MoreHide Full Article
Key Takeaways
Integrated Care delivered $394.3 million in revenues and $65.2 million in adjusted EBITDA in Q2 2026.
BetterHelp's shift to insurance contrasts with Integrated Care's enterprise contracts and chronic care growth.
Teladoc One will unite primary and chronic care services, strengthening Integrated Care's earnings role.
Teladoc Health, Inc.’s (TDOC - Free Report) Integrated Care is increasingly becoming the more dependable part of the business. Its growth is modest, but the segment is becoming more profitable as chronic care gains traction. That matters because Teladoc’s investment case is no longer solely about fixing BetterHelp. Increasingly, it hinges on whether Integrated Care can contribute a larger share of the company’s earnings as Teladoc builds a broader healthcare platform.
Integrated Care is now driving most of Teladoc’s earnings. The segment generated $394.3 million in revenue and $65.2 million in adjusted EBITDA in the second quarter, compared with just $0.5 million of adjusted EBITDA from BetterHelp. With consolidated adjusted EBITDA at $65.7 million, Integrated Care is clearly the primary driver of profitability.
The two businesses face very different economics. BetterHelp is dealing with the shift from cash-pay to insurance, while provider availability remains a constraint. Integrated Care runs on enterprise contracts and has more room to grow revenues through chronic care bundles and services like Teladoc One. That gives the segment a clearer path to expand without relying on a major increase in membership.
Teladoc One, set for broad launch in January 2027, will integrate primary care, chronic care and other services around the same patient. If adoption builds, Integrated Care could become Teladoc’s main earnings driver, giving the company a steadier path to profit growth even if overall membership growth remains modest.
How Are Competitors Faring?
Some of Teladoc’s key peers across digital health are Hims & Hers Health, Inc. (HIMS - Free Report) and Omada Health, Inc. (OMDA - Free Report) .
Hims & Hers Health operates a consumer-focused digital healthcare platform spanning areas such as weight management, sexual health, dermatology and mental health. Its direct-to-consumer model has helped HIMS scale quickly, making customer growth, engagement and marketing efficiency important drivers of its performance.
Omada Health focuses on virtual care for chronic conditions, including diabetes, hypertension, weight management and musculoskeletal conditions. It provides recurring access to a growing member base, while its multi-condition platform allows OMDA to expand relationships across different areas of care.
Shares of TDOC have gained 18.5% over the past six months compared with the industry’s 8.1% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, TDOC trades at a forward price-to-sales ratio of 0.47X, down from the industry average of 0.53X. TDOC carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TDOC’s 2026 loss is pegged at 89 cents per share,implying a 21.9% increase from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Teladoc's Integrated Care Business Deserves More Attention
Key Takeaways
Teladoc Health, Inc.’s (TDOC - Free Report) Integrated Care is increasingly becoming the more dependable part of the business. Its growth is modest, but the segment is becoming more profitable as chronic care gains traction. That matters because Teladoc’s investment case is no longer solely about fixing BetterHelp. Increasingly, it hinges on whether Integrated Care can contribute a larger share of the company’s earnings as Teladoc builds a broader healthcare platform.
Integrated Care is now driving most of Teladoc’s earnings. The segment generated $394.3 million in revenue and $65.2 million in adjusted EBITDA in the second quarter, compared with just $0.5 million of adjusted EBITDA from BetterHelp. With consolidated adjusted EBITDA at $65.7 million, Integrated Care is clearly the primary driver of profitability.
The two businesses face very different economics. BetterHelp is dealing with the shift from cash-pay to insurance, while provider availability remains a constraint. Integrated Care runs on enterprise contracts and has more room to grow revenues through chronic care bundles and services like Teladoc One. That gives the segment a clearer path to expand without relying on a major increase in membership.
Teladoc One, set for broad launch in January 2027, will integrate primary care, chronic care and other services around the same patient. If adoption builds, Integrated Care could become Teladoc’s main earnings driver, giving the company a steadier path to profit growth even if overall membership growth remains modest.
How Are Competitors Faring?
Some of Teladoc’s key peers across digital health are Hims & Hers Health, Inc. (HIMS - Free Report) and Omada Health, Inc. (OMDA - Free Report) .
Hims & Hers Health operates a consumer-focused digital healthcare platform spanning areas such as weight management, sexual health, dermatology and mental health. Its direct-to-consumer model has helped HIMS scale quickly, making customer growth, engagement and marketing efficiency important drivers of its performance.
Omada Health focuses on virtual care for chronic conditions, including diabetes, hypertension, weight management and musculoskeletal conditions. It provides recurring access to a growing member base, while its multi-condition platform allows OMDA to expand relationships across different areas of care.
Teladoc Health’s Price Performance, Valuation & Estimates
Shares of TDOC have gained 18.5% over the past six months compared with the industry’s 8.1% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, TDOC trades at a forward price-to-sales ratio of 0.47X, down from the industry average of 0.53X. TDOC carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TDOC’s 2026 loss is pegged at 89 cents per share,implying a 21.9% increase from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.